Trulieve Cannabis Corp. quarterly report, Q1 FY2023

Trulieve Cannabis Corp. — Q1 2023 Form 10-Q

Reporting period: Three months ended March 31, 2023; unaudited results, compared with Q1 2022. Unless stated otherwise, amounts are U.S. dollars. The results reflect continuing operations; Nevada operations are presented as discontinued operations following the 2022 exit.

Business context

Trulieve is a vertically integrated cannabis operator active in 11 states. At quarter-end it operated 184 dispensaries and 18 cultivation and processing facilities, and employed more than 5,900 people. Florida is its cornerstone market. The company reported increased competition and promotional activity in Florida, Pennsylvania, and Massachusetts.

Financial performance

MetricQ1 2023Q1 2022Change
Revenue, net$289.1m$317.7mDown $28.7m, or 9%
Gross profit$149.9m$180.5mDown $30.5m, or 17%
Gross margin51.9%56.8%Down 4.9 percentage points
Operating income (loss)($13.1m)$29.2mDown $42.3m
Net loss from continuing operations($65.7m)($30.1m)Loss increased $35.6m
Net loss attributable to common shareholders($64.1m)($32.0m)Loss increased $32.1m
Adjusted EBITDA (non-GAAP)$78.2m$105.4mDown $27.3m, or 26%

Retail revenue was $275.7m, down from $290.6m; wholesale, licensing, and other revenue was $13.4m, down from $27.1m. Management attributed weaker gross margin to promotional activity, a shift toward value brands, inventory-reduction initiatives, higher depreciation, and lower-margin sales of third-party products in markets where operations are not fully vertically integrated.

Sales and marketing expense declined 14% to $62.3m, partly from staffing adjustments. General and administrative expense rose 17% to $39.4m, including a $10.5m contribution to the Smart and Safe Florida campaign. Depreciation and amortization was $30.4m. Interest expense increased to $22.7m from $17.9m. The income-tax provision was $35.0m despite a pretax loss, reflecting, among other factors, cannabis-related limits on deductions under IRC Section 280E.

Cash flow, liquidity, and debt

  • Cash and cash equivalents were $188.1m at March 31, 2023; restricted cash was $7.2m. Cash, cash equivalents, and restricted cash totaled $195.3m, down from $218.9m at year-end 2022.
  • Operating cash flow was $0.4m, versus $45.1m in Q1 2022. Management said the decline was primarily driven by $46.3m of income-tax payments deferred from Q4 2022 because of Hurricane Ian and paid in Q1 2023, as well as weaker operating results.
  • Investing cash outflow was $18.8m, compared with $83.8m in the prior-year quarter. Financing cash outflow was $5.8m, versus $72.2m of inflow, which included $76.4m of private-placement proceeds in Q1 2022.
  • At quarter-end, notes payable had a $105.1m gross balance and private-placement notes totaled $555.0m gross ($543.0m net carrying value). The private notes mature in 2024 and 2026; $425m of principal is due in 2026. The filing also reports substantial lease and construction-finance obligations.
  • Contractual obligations totaled $1.501bn, including notes, private-placement notes, leases, construction-finance liabilities, and lease settlements. Management said available cash should cover anticipated needs for at least 12 months from the filing date.

Material changes, outlook, and risks

  • Long-lived asset impairment and disposal expense was $31.0m, including a $30.3m impairment in Massachusetts, primarily involving intangible assets. The company’s interim goodwill test found no impairment.
  • The company reduced deferred revenue by $4.7m after terminating a Harvest-acquired dispensary loyalty program; the reduction was recorded in revenue.
  • Trulieve exited Nevada in 2022. The quarter included $48,000 of income from discontinued operations, compared with a $2.4m loss in Q1 2022.
  • Management provided no quantified revenue or earnings guidance. It expects sales and marketing costs to increase over the long term as it expands dispensaries, and said it expects continued investment in general and administrative capabilities. Georgia stores opened after quarter-end, on April 28, 2023; adult-use sales began in Connecticut in February 2023.
  • Risks include federal cannabis prohibition and potential enforcement or asset forfeiture; competition and pricing pressure; restrictive cannabis taxation; limited access to banking; licensing and regulatory compliance; and significant debt obligations. The filing added risks relating to uninsured bank deposits and financial-sector disruption.
  • Management disclosed that disclosure controls and procedures were not effective at March 31, 2023 because previously identified material weaknesses—in IT controls, inventory valuation, and variable-interest-entity controls—were still being remediated. Management stated the financial statements fairly present the company’s results in all material respects.
  • The balance sheet included $25.5m of contingencies, principally litigation and sales-tax matters. The company also disclosed that it settled a Watkins acquisition earnout matter in May 2023, after quarter-end. In May, it amended certain loan covenant calculations to exclude balloon payments.

Most important facts for investors to verify

  • Whether revenue and gross margin stabilize amid competition, promotions, and lower wholesale sales.
  • Whether operating cash flow improves after the unusually large Q1 tax payment, and how cash balances trend against debt service and contractual obligations.
  • Whether the Massachusetts impairment signals further asset-value pressure, and whether goodwill assumptions remain supportable.
  • Progress in remediating the disclosed material weaknesses, including evidence that controls operate effectively.
  • Compliance with debt covenants, including the effect of the May 2023 amendment, and the company’s ability to manage 2024 and 2026 debt maturities.
  • Developments in federal cannabis policy, state regulation, IRC Section 280E, banking access, litigation, and other contingencies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.